Lobo Genetics

lobogene.com

Lobo Genetics enables safer cannabis use through DNA testing. Consumers and patients can gain actionable insights into their personal response to cannabis based on their genetic profile. Lobo's portable device platform provides results in under an hour, and can be deployed in medical clinics, dispensaries, pharmacies or retail outlets. With applications across the recreational, medical and clinical space, Lobo is bringing the science of cannabis genetics to everyone.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

news image

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More

Industrial Impact

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

news image

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More

Cell and Gene Therapy

BICYCLE THERAPEUTICS ANNOUNCES BT5528 PHASE I DOSE ESCALATION RESULTS IN PATIENTS WITH ADVANCED SOLID TUMORS

Bicycle Therapeutics | September 08, 2022

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors. “The therapeutic profile from the dose escalation portion of the Phase I/II trial of BT5528 in patients with late-line disease suggests...

Read More

Cell and Gene Therapy

MRNA VICTORIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO GROW THE BIOECONOMY & INTERNATIONAL BIOSECURITY CAPABILITIES

Ginkgo Bioworks, mRNA Victoria | November 18, 2021

news image

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first ...

Read More
news image

Industrial Impact

PARTEK AND AGILENT PARTNER TO DELIVER ALISSA CUSTOMERS END-TO-END BIOINFORMATICS WORKFLOW

Partek® Incorporated | August 20, 2021

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow softw...

Read More
news image

Industrial Impact

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More
news image

Cell and Gene Therapy

BICYCLE THERAPEUTICS ANNOUNCES BT5528 PHASE I DOSE ESCALATION RESULTS IN PATIENTS WITH ADVANCED SOLID TUMORS

Bicycle Therapeutics | September 08, 2022

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors. “The therapeutic profile from the dose escalation portion of the Phase I/II trial of BT5528 in patients with late-line disease suggests...

Read More
news image

Cell and Gene Therapy

MRNA VICTORIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO GROW THE BIOECONOMY & INTERNATIONAL BIOSECURITY CAPABILITIES

Ginkgo Bioworks, mRNA Victoria | November 18, 2021

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us